Childhood vaccination schedule: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
Line 8: Line 8:
==Childhood vaccination schedule==
==Childhood vaccination schedule==
The following table summarizes the vaccination schedule for Adolescents Aged 18 Years or Younger based on CDC 2017 recommendation.
The following table summarizes the vaccination schedule for Adolescents Aged 18 Years or Younger based on CDC 2017 recommendation.
{| class="wikitable"
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center
!Vaccine
! align="center" style="background:#4479BA; color: #FFFFFF;" |Vaccine
!Birth
! align="center" style="background:#4479BA; color: #FFFFFF;" |Birth
!1 mo
! align="center" style="background:#4479BA; color: #FFFFFF;" |1 mo
!2 mos
! align="center" style="background:#4479BA; color: #FFFFFF;" |2 mos
!4 mos
! align="center" style="background:#4479BA; color: #FFFFFF;" |4 mos
!6 mos
! align="center" style="background:#4479BA; color: #FFFFFF;" |6 mos
!9 mos
! align="center" style="background:#4479BA; color: #FFFFFF;" |9 mos
!12 mos
! align="center" style="background:#4479BA; color: #FFFFFF;" |12 mos
!15 mos
! align="center" style="background:#4479BA; color: #FFFFFF;" |15 mos
!18 mos
! align="center" style="background:#4479BA; color: #FFFFFF;" |18 mos
!19-23 mos
! align="center" style="background:#4479BA; color: #FFFFFF;" |19-23 mos
!2-3 yrs
! align="center" style="background:#4479BA; color: #FFFFFF;" |2-3 yrs
!4-6 yrs
! align="center" style="background:#4479BA; color: #FFFFFF;" |4-6 yrs
!7-10 yrs
! align="center" style="background:#4479BA; color: #FFFFFF;" |7-10 yrs
!11-12 yrs
! align="center" style="background:#4479BA; color: #FFFFFF;" |11-12 yrs
!13-15 yrs
! align="center" style="background:#4479BA; color: #FFFFFF;" |13-15 yrs
!16 yrs
! align="center" style="background:#4479BA; color: #FFFFFF;" |16 yrs
!17-18 yrs
! align="center" style="background:#4479BA; color: #FFFFFF;" |17-18 yrs
|-
|-
|Hepatitis B1 (HepB)
|align="center" style="background:#DCDCDC;"|Hepatitis B1 (HepB)
|1st dose
|style="background: #F0E68C; padding: 5px text-align:center" |1st dose
| colspan="2" |2nd dose
| colspan="2" style="background: #F0E68C; padding: 5px text-align:center" |2nd dose
|
|style="background: #AFEEEE; padding: 5px text-align:center" |
| colspan="5" |3rd dose
| colspan="5" style="background: #F0E68C; padding: 5px text-align:center" |3rd dose
|
|
|
|
Line 42: Line 42:
|
|
|-
|-
|Rotavirus2 (RV) RV1 (2-dose series);
|align="center" style="background:#DCDCDC;"|Rotavirus2 (RV) RV1 (2-dose series);
RV5 (3-dose series)
RV5 (3-dose series)
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|1st dose
|style="background: #F0E68C; padding: 5px text-align:center" |1st dose
|2nd dose
|style="background: #F0E68C; padding: 5px text-align:center" |2nd dose
|See footnote 2
|style="background: #F0E68C; padding: 5px text-align:center" |See footnote 2
|
|
|
|
Line 62: Line 62:
|
|
|-
|-
|Diphtheria, tetanus, & acellular pertussis3
|align="center" style="background:#DCDCDC;"|Diphtheria, tetanus, & acellular pertussis3
(DTaP: <7 yrs)
(DTaP: <7 yrs)
|style="background:#F8F8FF; |
|style="background:#F8F8FF; |
|style="background: #F0E68C; padding: 5px text-align:center" |1st dose
|style="background: #F0E68C; padding: 5px text-align:center" |2nd dose
|style="background: #F0E68C; padding: 5px text-align:center" |3rd dose
|
|
|
|
|1st dose
| colspan="2" style="background: #F0E68C; padding: 5px text-align:center" |4th dose
|2nd dose
|3rd dose
|
|
| colspan="2" |4th dose
|
|
|
|
|5th dose
|style="background: #F0E68C; padding: 5px text-align:center" |5th dose
|
|
|
|
Line 81: Line 81:
|
|
|-
|-
|Haemophilus influenzae type b4 (Hib)
|align="center" style="background:#DCDCDC;"|Haemophilus influenzae type b4 (Hib)
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|1st dose
|style="background: #F0E68C; padding: 5px text-align:center" |1st dose
|2nd dose
|style="background: #F0E68C; padding: 5px text-align:center" |2nd dose
|See footnote 4
|See footnote 4
|
|
| colspan="2" |3rd or 4th dose,  
| colspan="2" style="background: #F0E68C; padding: 5px text-align:center" |3rd or 4th dose,  
See footnote 4
See footnote 4
|
|
Line 100: Line 100:
|
|
|-
|-
|Pneumococcal conjugate5 (PCV13)
|align="center" style="background:#DCDCDC;"|Pneumococcal conjugate5 (PCV13)
|style="background:#F8F8FF; |
|style="background:#F8F8FF; |
|style="background: #F0E68C; padding: 5px text-align:center" |1st dose
|style="background: #F0E68C; padding: 5px text-align:center" |2nd dose
|style="background: #F0E68C; padding: 5px text-align:center" |3rd dose
|
|
|
| colspan="2" style="background: #F0E68C; padding: 5px text-align:center" |4th dose
|1st dose
|2nd dose
|3rd dose
|
| colspan="2" |4th dose
|
|
|
|
Line 118: Line 118:
|
|
|-
|-
|Inactivated poliovirus6 (IPV: <18 yrs)
|align="center" style="background:#DCDCDC;"|Inactivated poliovirus6 (IPV: <18 yrs)
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|1st dose
|style="background: #F0E68C; padding: 5px text-align:center" |1st dose
|2nd dose
|style="background: #F0E68C; padding: 5px text-align:center" |2nd dose
| colspan="5" |3rd dose
| colspan="5" style="background: #F0E68C; padding: 5px text-align:center" |3rd dose
|
|
|
|
|4th dose
|style="background: #F0E68C; padding: 5px text-align:center" |4th dose
|
|
|
|
Line 133: Line 133:
|
|
|-
|-
|Influenza7 (IIV)
|align="center" style="background:#DCDCDC;"|Influenza7 (IIV)
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
| colspan="9" |Annual vaccination (IIV) 1 or 2 doses
| colspan="9" style="background: #F0E68C; padding: 5px text-align:center" |Annual vaccination (IIV) 1 or 2 doses
| colspan="4" |Annual vaccination (IIV) 1 dose only
| colspan="4" style="background: #F0E68C; padding: 5px text-align:center" |Annual vaccination (IIV) 1 dose only
|-
|-
|Measles, mumps, rubella8 (MMR)
|align="center" style="background:#DCDCDC;"|Measles, mumps, rubella8 (MMR)
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
| colspan="2" |See footnote 8
| colspan="2" |See footnote 8
| colspan="2" |1st dose
| colspan="2" style="background: #F0E68C; padding: 5px text-align:center" |1st dose
|
|
|
|
|
|
|2nd dose
|style="background: #F0E68C; padding: 5px text-align:center" |2nd dose
|
|
|
|
Line 158: Line 158:
|
|
|-
|-
|Varicella9 (VAR)
|align="center" style="background:#DCDCDC;"|Varicella9 (VAR)
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
| colspan="2" |1st dose
| colspan="2" style="background: #F0E68C; padding: 5px text-align:center" |1st dose
|
|
|
|
|
|
|2nd dose
|style="background: #F0E68C; padding: 5px text-align:center" |2nd dose
|
|
|
|
Line 176: Line 176:
|
|
|-
|-
|Hepatitis A1 0 (HepA)
|align="center" style="background:#DCDCDC;"|Hepatitis A1 0 (HepA)
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
| colspan="4" |2-dose series, See footnote 10
| colspan="4" style="background:#F0E68C; |2-dose series, See footnote 10
|
|
|
|
Line 192: Line 192:
|
|
|-
|-
|Meningococcal1 1 (Hib-MenCY >6 weeks;  
|align="center" style="background:#DCDCDC;"|Meningococcal1 1 (Hib-MenCY >6 weeks;  
MenACWY-D >9 mos; MenACWY-CRM ≥2 mos)
MenACWY-D >9 mos; MenACWY-CRM ≥2 mos)
|style="background:#F8F8FF; |
|style="background:#F8F8FF; |
|
|
|
|
Line 205: Line 207:
|
|
|
|
|style="background: #F0E68C; padding: 5px text-align:center" |1st dose
|
|
|
|style="background: #F0E68C; padding: 5px text-align:center" |2nd dose
|1st dose
|
|2nd dose
|
|
|-
|-
|Tetanus, diphtheria, & acellular pertussis12 (Tdap: >7 yrs)
|align="center" style="background:#DCDCDC;"|Tetanus, diphtheria, & acellular pertussis12 (Tdap: >7 yrs)
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|style="background:#F8F8FF; |
|style="background:#F8F8FF; |
|style="background:#F8F8FF; |
|style="background:#F8F8FF; |
|style="background:#F8F8FF; |
|style="background:#F8F8FF; |
|style="background:#F8F8FF; |
|style="background:#F8F8FF; |
|style="background:#F8F8FF; |
|
|
|
|style="background:#F0E68C; |Tdap
|
|
|
|
|
|
|
|
|Tdap
|
|
|
|
|
|
|-
|-
|Human papillomavirus1 3 (HPV)
|align="center" style="background:#DCDCDC;"|Human papillomavirus1 3 (HPV)
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|
|See footnote 13
|See footnote 13
Line 250: Line 250:
|
|
|-
|-
|Meningococcal B1 1
|align="center" style="background:#DCDCDC;"|Meningococcal B1 1
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|
|
|
Line 269: Line 269:
|
|
|-
|-
|Pneumococcal polysaccharide5 (PPSV23)
|align="center" style="background:#DCDCDC;"|Pneumococcal polysaccharide5 (PPSV23)
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|style="background:#F8F8FF; |
|
|
|
|
Line 288: Line 288:
|
|
|}
|}


==See also==
==See also==

Revision as of 19:22, 10 April 2017

Template:Vaccination schedule Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2]

Overview

Childhood vaccination schedule

The following table summarizes the vaccination schedule for Adolescents Aged 18 Years or Younger based on CDC 2017 recommendation.

Vaccine Birth 1 mo 2 mos 4 mos 6 mos 9 mos 12 mos 15 mos 18 mos 19-23 mos 2-3 yrs 4-6 yrs 7-10 yrs 11-12 yrs 13-15 yrs 16 yrs 17-18 yrs
Hepatitis B1 (HepB) 1st dose 2nd dose 3rd dose
Rotavirus2 (RV) RV1 (2-dose series);

RV5 (3-dose series)

1st dose 2nd dose See footnote 2
Diphtheria, tetanus, & acellular pertussis3

(DTaP: <7 yrs)

1st dose 2nd dose 3rd dose 4th dose 5th dose
Haemophilus influenzae type b4 (Hib) 1st dose 2nd dose See footnote 4 3rd or 4th dose,

See footnote 4

Pneumococcal conjugate5 (PCV13) 1st dose 2nd dose 3rd dose 4th dose
Inactivated poliovirus6 (IPV: <18 yrs) 1st dose 2nd dose 3rd dose 4th dose
Influenza7 (IIV) Annual vaccination (IIV) 1 or 2 doses Annual vaccination (IIV) 1 dose only
Measles, mumps, rubella8 (MMR) See footnote 8 1st dose 2nd dose
Varicella9 (VAR) 1st dose 2nd dose
Hepatitis A1 0 (HepA) 2-dose series, See footnote 10
Meningococcal1 1 (Hib-MenCY >6 weeks;

MenACWY-D >9 mos; MenACWY-CRM ≥2 mos)

1st dose 2nd dose
Tetanus, diphtheria, & acellular pertussis12 (Tdap: >7 yrs) Tdap
Human papillomavirus1 3 (HPV) See footnote 13
Meningococcal B1 1
Pneumococcal polysaccharide5 (PPSV23)

See also

Sources and notes

External links

  • National Center for Immunization and Respiratory Diseases. "CDC National Immunization Program". CDC. Retrieved 2006-09-18.
  • "MMR vaccine and the autism epidemic: In a compulsory inoculation program, it is the responsibility of the developers, promoters and enforcers to prove safety and efficacy". MMR vaccine and the autism epidemic. InformedChoice.info. Retrieved 2006-09-18.
  • National Health Service of UK. "UK Immunisation Schedule and Information". NHS. Retrieved 2006-11-03.

Template:Vaccines

de:Impfkalender id:Jadwal imunisasi


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Childhood_vaccination_schedule&oldid=1306242"